Qiagen provides sample-to-insight technologies for molecular testing in life sciences research and clinical diagnostics. Its portfolio covers nucleic-acid extraction, reagents, assay kits and automated instruments used in PCR, sequencing workflows and pathogen detection. Customers range from academic labs and biopharma to hospitals and public-health laboratories that need reliable sample preparation and molecular analysis.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 533.5 | — | 96.3 | — |
| Q3 2025 | 532.6 | — | 130 | — |
| Q4 2025 | 540.4 | — | 107.8 | — |
| Q1 2026 | 492.3 | — | 68 | — |
| Q2 2026 | 535 | 0.3% | 103.4 | 7.4% |
All markets — KeepWinning global stock screener
Other companies on NYSE: The Toro Company (TTC), Aptiv PLC (APTV), Bio-Rad Laboratories, Inc. (BIO), New Oriental Education & Technology Group Inc. (EDU), SM Energy Company (SM), TFI International Inc. (TFII)